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  INTRODUCTION 
 
 Periampullary carcinoma is a distinct clinicopathological entity arising 
within 2 cm of the major papilla in the duodenum. They encompass four different 
types of cancers: 
1. ampullary( ampulla of vater)  
2. Biliary (intrapancreatic distal bile duct) 
3. Pancreatic (head –Uncinate process)  
4. Duodenal( mainly from the second portion) 
70% to 80% of theses tumors are well differentiated adenocarcinomas. 
Although, these tumors have different orgin, the complex regional anatomy and 
their proximation within that confined region generally dictate a common 
operative approach.  
 Radical resections, such as the whipple’s procedure or its variant with 
preservation of the pylorus with or without extended regional lymphadenectomy, 
have been the main treatments for these cancers, especially with the currently low 
morbidity and mortality rates. Although the perioperative outcomes for these 
different cancers are similar, the long term survival has traditionally varied. 
Consequently, as the exact tumor origin is often difficult to clinically ascertain, 
surgeons have favored an aggressive approach toward resection to benefit those 
patients harboring cancers with a better prognosis. 
 It is unknown why outcome should vary for adenocarcinomas arising from 
different anatomic sites in such close proximity. Indeed, if survival does vary 
significantly for those cancers as clinical impression suggests, clearly, factors 
other than anatomy must also be involved.  
              Since, Periampullary carcinoma is one of the commonest cause of 
obstructive jaundice & highest cure rate following resection  is possible, this study 
is undertaken to know the differences in the clinical behavior of the Periampullary 
carcinoma and to define which of these factors, affect the disease outcome and 
alter the survival. 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
1. To evaluate the incidence of Periampullary carcinoma in TMCH from June 
2004 to October 2006.  
2. To know the aetiological and epidemiological factors associated with these 
cancers. 
3. To know the clinical manifestation and investigations to aid the diagnosis and 
assess the resectability of these tumors.  
4. To study the treatment instituted and the management of complications  
5. To review the literature on the subject. 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
EMBRYOLOGY 
 The caudal foregut and the cranial midgut generate the duodenum. The 
origin of the bile duct, the pancreas, and the ampulla of vater arise from the 
foregut just above its junction with the midgut. 
 
 Embryologically and anatomically, patterns of periampullary cancer 
spread should be similar for pancreatic, ampullary and distal bile duct cancers 
because they are foregut derivatives. In contrast, infra-ampullary duodenal cancers 
should spread along the superior mesenteric or midgut pathways. 
 
Because of the ambiguous lymphatic drainage of the head of pancreas, 
lymphatic metastases from pancreatic cancers are less predictable and are likely to 
extend along the foregut and midgut pathways. 
 
Invasion of the pancreas by nonpancreatic periampullary cancers likely 
predisposes to similar patterns of spread. Because most periampullary cancers 
arise commonly from the distal foregut, anatomic or embryologic factors likely 
contribute little to differences in outcome. 
 
 
SURGICAL ANATOMY 
Pancreas 
Glandular and Retroperitoneal organ, transversely placed at L1 level (12 – 
20cm long, 60 – 125g wt), and has close proximity to many organs and great 
vessels leads to early local invasion 
 Related to omental bursa above and greater sac below, Anterior–transverse 
mesocolon, Posterior–avscular fusion planes of Toldt and Treitz. 
 Arbitrarily divided into head, neck, body & tail 
• Head – Rt. of SMV (45—50% of gland) 
• Neck – on Superior Mesenteric Vessels 
• Body & tail – lateral to Lt. Bolder of SMV 
• Uncinate process. 
 
Head of Pancreas 
• Widest and thickest part of the gland 
• intimately  fit into the C loop of duodenum 
• Anterior – pylorus,transverse colon ,mesocolon and anterior arcade of vessels 
• Posterior - avasclar fasciae of Treitz separates from the retroperiponeal 
structures 
 
 
Arterial supply 
Gatroduodenal and SMA form anterior & posterior. arcades over the Head.  
Anterior & Posterior Pancreaticoduodenal arteries supplies head of pancreas and 
duodenum. This intimate blood supply is one reason for combined 
pancreaticoduodenal resection. 
 Anterior Arcade lies embedded in the pancreatic substance and close to 
duodenum. 
 Posterior Arcade lies away from duodenum and outside the pancreas.  
 Inferior PD arteries may arise from 1st jejunal branch, ligation of this may 
endanger DJ flexure. 
 
Anomalies which cause concern in pancreatic surgery are aberrant common 
hepatic from SMA, Acessory Rt.HA from SMA, Acessory Lt. HA from 
gastroduodenal or from Rt. Side of SMA. 
 
Venous Drainage 
 Both arteries & veins lie posterior to duct and veins draining the pancreatic 
parenchyma eventually terminate into portal vein and its major tributaries. Small 
veins enter major veins laterally, this facilitates assessment by finger between neck 
and portal vein so also the dissection 
 
 
Lymphatic drainage 
Rich perilobular network draining into all direction posing challenge to 
oncological resection. Lymphatics  drain to  the nodes in the pancreatico duodenal 
groove. These nodes are anterior and posterior pancreatico duodenal,superior and 
inferior head nodes, from these nodes, lymph drains to the portal, coeliac, 
mesenteric and para-aortic nodes. 
 
Innervation 
             Sympathetic post ganglionic fibers from the coelic ganglion serve as the 
principal pathways for pain of pancreatic origin. Parasympathetic fibers from 
vagus serve as an exclusive efferent function. 
 
Structure and Histology  
              Of the pancreatic mass, 80-90% is composed of exocrine tissue, 
remaining is endocrine tissue. The pancreatic duct is lined by columnar epithelium  
from which most of the cancers arise. 
 
                The mucosa of the ampulla of Vater is lined by columnar epithelium and 
is thrown into longitudinal folds likened to mucosal valvules. 
 
 
 
Ampulla of Vater  
Papilla is present in the posteromedial wall of the second part of duodenum 
8to 10 cms distal to pylorus. In the papilla, there is the ampulla of Vater into 
which both pancreatic and common bile duct open. The ampulla of Vater is 
guarded by sphinter known as the Sphinter of Oddi, which regulates flow into the  
duodenum & gallbladder filling, and resists reflux of duodenal contents. Proximal 
to the sphinter of oddi, distal common bileduct is guarded by sphincter 
choledochus known as Sphinter of Boyden and pancreatic duct is guarded by 
sphinter Pancreaticus. The oblique passage of the ducts through the duodenal 
wall and the presence of mucosal valvules may also help to prevent reflux. 
Common bile duct 
 It is divided into supra duodenal, retroduodenal, infraduodenal and 
intraduodenal part. The infra duodenal part, that is the retropancreatic portion, runs 
in groove or tunnel in the pancreas, approaches the second part of duodenum 
obliquely accompanied by the terminal part of pancreatic duct.  
 Blood Supply of lower CBD - superior pancreaticoduodenal Artery 
 Venous drainage – portal vein 
 Lymphatic drainage – Lower hepatic node, upper pancreatico splenic node 
 Nerve Supply – plexus over the superior pancreaticoduodenal Artery. 
 
Second part of the duodenum  
 7.5 cms in lengths, hugs the head of pancreas. 
 Supplied by superior and inferior pancreatico duodenal arteries. 
 Venous drainage – spleenic, Sup. Mesenteric and portal vein 
SURGICAL PHYSIOLOGY 
 
 In response to a meal, the pancreas secretes digestive enzymes in an 
alkaline (pH 8.4) bicarbonate-rich fluid. Spontaneous secretion is minimal the 
hormone secretion, which is released from the duodenal mucosa, evokes a 
bicarbonate-rich fluid. Cholecystokinin (CCK) is released from the duodenal 
mucosa in response to food: CCK produces no increase in the volume of secretion 
but is responsible for enzyme secretion. Vagal stimulation increases volume. 
Protein is synthesized at a greater rate (per gram of tissue) in the pancreas than in 
any other tissue, with the possible exception of the lactating mammary gland. 
About 90 % of this protein is exported from the acinar cells as a variety of 
digestive enzymes. Approximately 6 – 20 g of digestive enzymes enters the 
duodenum each day.  Nascent proteins are synthesized as preproteins, and during   
their transit through the rough endoplasmic reticulum Golgi cistranae the newly 
synthesized proteins undergo modification in a sequence of steps. The proteins 
move from the rough ER to Golgi complex, lysomes and mature zymogen storage 
granules containing proteases are stored, and move to the ductal surface of the 
cell, from which they are extruded by exostosis. During this phase, the proteolytic 
enzymes are in an inactive form, the maintenance of which is important in 
preventing pancreatitis. 
 
Bile, as it leaves the liver, is composed of 97 % water, 1 – 2 % bile salts 
and 1 % pigments, cholesterol and fatty acids. The liver excretes bile at a rate 
estimated to be approximately 40 ml/hr. The rate of bile secretion is controlled by 
cholecystokinin, which is released from the duodenal mucosa. With feeding there 
is increased production of bile. 
 
PATHOLOGY 
  Accurate histological classification of periampullary cancers can be 
notoriously difficult. Two practical points are useful in defining the orgin of these 
cancers, the predominent site of mass, the presence of any component of 
carcinoma in situ.  
 
Periampullary cancers are derived from their respective epithelia and 
almost all are adenocarcinomas. Duodenal cancers can be classified 
morphologically as polypoid, flat elevated and ulcerative-invasive; Ampullary and 
biliary cancers are classified as papillary, nodular and sclerosing types. Regardless 
of orgin, polypoid and papillary cancers have been associated with better 
prognosis. 
     The degree of cancer cell differentiation varies widely among the 
periampullary cancers. Undifferentiation (higher histopathlogical grade), is 
greatest for pancreatic cancers and least for ampullary cancers.  
Zhu et al address similarities between duodenal and ampullary cancers.  
CEA in 73% of duodenal and 63% of ampullary cancers,  p53 in 20% duodenal 
and 13% ampullary cancers, c-neu in 60% duodenal and 100% ampullary cancers. 
 
Longnecker et al compared histologic findings between distal bileduct and 
pancreatic cancers. Desmoplasia was common in both cancers. And both had 
propensity for perineural invasion. Moreover, molecular and pathological features 
of oncogene and tumorsuppresor genes were similar and did not help to 
differentiate between the two cancers. 
 Ebert et al evaluated the presence of mutation on k-ras oncogene at codon 
12, which has been traditionally expressed in more than 80% of pancreatic 
cancers. Ampullary cancers had mutations at codon 13. 
 
Friess et al suggest a different molecular pathway in the development of 
ampullary and pancreatic cancers. The lack of upregulation of EGFR( epidermal 
growth factors)  in ampullary cancers could partly account for their less aggressive 
behaviour (a different phenotype). 
 
Markers of tumor biology in periampullary cancers suggest that genetic 
differences between these cancers probably contribute significantly toward 
phenotypic differences and the perceived clinical differences among periampullary 
cancers. 
Pathological examination of resected specimens showed that adenocarcinoa 
of head of pancreas was 40 to 60 % ampulla of Vater  20 to 40%, distal CBD 10%, 
and duodenum 10%  But, overall, the carcinoma of head of pancreas is the likely 
site of orgin upto 90% of cases. 
 
The majority of carcinoma of ampulla Vater, appear to be the intestinal type 
and show histological resemblance to colorectal adenocarcinoma. 
 
Cattell and Pyrtek first reported malignant transformation of an adenoma 
of papilla. In more than 70% of investigated carcinomas of ampulla, tissue 
samples were found with severe dysplasia. At present there are substantial 
arguments, including molecular biological data, for hypothesis of an adenoma- 
dysplasia- carcinoma sequence of neoplastic lesion of ampulla. A villous adenoma 
of ampulla of Vater is considered as a premalignant lesion, with the consequence 
of complete extirpation of the lesion to avoid development of cancer. The 
frequency of a malignant lesion in an adenoma of the papilla is around 26%. 
 
 
 
 
 
 
EPIDEMIOLOGIC CONSIDERATIONS 
 
INCIDENCE 
           Overall Periampullary cancers account for 5% all GIT malignancies. 
Pancreatic cancer occurs most often among periampullary cancers. They account 
for 3% of all GIT cancers. Ampulla of Vater represents less than 1% and 
adenocarcinoma of duodenum represents about 0.5% of all GIT cancers. 
Carcinoma of ampulla of vater occur more frequently than distal CBD cancer with 
a ratio of 1:12 
AGE 
The incidence of periampullary carcinoma increases steadily with 
increasing age, and over 80 % of the patients seen in 6-8 decade of life. 
SEX 
 The male to female ratio is usually reported as between 1.5 : 1 to 2 :1. 
PREVALENCE  
Surgeons should recognize the reports on operative result do not represents 
their actual incidents. Among resected Periampullary cancers, Ca .of head of 
Pancreas accounts for 50% to 70% Ampullary cancers for 15% to 25% Biliary 
cancers for 10% and duodenal cancers for 10%. These data reflect the             
prevalence of resected cancers.  
Overall, perioperative mortality and morbidity for each cancers are similar, 
0% to 15% and 30% to 50% respectively 
SURVIVAL 
Survival is greatest for ampullary and duodenal cancers and is intermediate 
for biliary cancers & least for pancreatic cancers. 
 
           Although the perioperative outcome for these different cancers are similar, 
the long term survival has traditionally varied. It is unknown why outcome should 
vary for adenocarcinoma arising from different anatomic sites in such close 
proximity. 
 
AETIOLOGY AND RISK FACTORS 
I. ENVIRONMENTAL 
1. Cigarette Smoking 
 This is only environmental factor that has been consistently associated with 
the pancreatic cancer. There is 2-3 fold increase in risk. The mechanism appears to 
be related to tobacco specific nitrosamines. 
 
Alternatively, smoking can elevate blood lipids which may also increase 
the risk of pancreatic cancers. There is a dose relationship to the number of 
cigarettes smoked and the occurrence of pancreatic cancer. Upto 25 % of 
pancreatic carcinoma is believed to be attributable to cigarette smoking. 
 
2. Diet  
A high intake of fat, meat or both increase the risk by 1.5 times. Whereas 
the intake of fresh fruits and vegetables appears to have a protective effect. The 
diets high in fat stimulate cholecystokinin release which may induce pancreatic 
ductal hyperplasia and hypertrophy of acinar cells increased diatary protein 
associated with meat intake affect pancreatic enzyme out put. 
 
3. Ethanol 
The evidence at the present time does not support the view that it is a risk 
factor. 
 
4. Coffee 
A case control study in Japan and a metanalysis of data published between 
1981 and 1983 did not support the notion that either caffeinated or decaffeinated 
coffee or teas were risk factors for pancreatic cancer. 
 
5. Toxic Substances 
Pancreatic cancer as well as bile duct cancer has been associated with 
occupational exposures to 2 – Naphthylamine and benzidine. 
 
 
 
II. MEDICAL CONDITIONS 
 
1. Pancreatitis 
Tropical and hereditary pancreatitis are associated with increased incidence 
of pancreatic cancer. A multicenter International study found that 1.8 % of patients 
with chronic pancreatitis developed pancreatic cancer during a mean follow up of 
7.4 years. Occasionally a patient may present with acute pancreatitis as the first 
manifestation of carcinoma. 
2. Partial Gastrectomy 
There is 5-7 times increased incidence of pancreatic cancer after 15-20 years of 
partial gastrectomy. It may be related to increased production of nitrosamines. 
3. Cholecystectomy 
Increased endogenus production of cholecystokinin can be seen in patients 
following this surgery, which has also been associated with increased risk of 
pancreatic carcinoma. 
4. Diabetes Mellitus 
There is no consistent epidemiological association with diabetes mellitus 
and periampullary carcinoma. But this association appears to be the result of 
destruction of pancreatic tissues owing to the obstructing periampullary cancer and 
the resultant endocrine deficiency. Therefore, as with chronic pancreatitis the 
development of diabetes in patients after 40 years of age should be considered a 
clue to the diagnosis of pancreatic cancer. 
5. Adenoma 
There is a hypothesis of adenoma-dysplasia carcinoma sequence of 
neoplastic lesions of ampulla. A villous adenoma of ampulla of Vater is 
considered as premalignant lesion, with the frequency of 26 % malignant 
transformation. 
 
III. MOLECULAR GENETIC FACTORS 
 There is a association of familial polyposis of the colon and Gardner’s 
syndrome with the periampullary carcinoma. In both conditions, adenomatous 
polyps of the duodenum or ampulla predispose to the development of carcinoma. 
The risk is 200 times that of the normal population. 
 
 There is association of hereditary pancreatitis, Von Hippel – Lindau’s 
Syndrome, Lynch’s Syndrome II and ataxia telangiectasis with pancreatic 
cancer. 
 
 Molecular abnormalities includes a mutant C-Kirsten-eas (c-ki-ras) gene on 
codon 12 (upto 85%), and c-fos. Loss or a mutation of the p53 tumorsuppressor 
Gene at the locus 17p 13 (50-70%) and over expression of EGF receptor are also 
associated with pancreatic cancer. 
 
 
CLINICAL PRESENTATION 
 
 The early symptoms are usually vague and include anorexia, weight loss, 
abdominal discomfort and nausea. Specific symptoms develop only after invasion 
or obstruction of near by structure. 
Jaundice: 
 This is the specific symptom with which the patient presents. It is 
progressive in nature, and associated with pruritus which is due to irritation of 
cutaneous sensory nerves by retained bile salts. Pruritus relieved by bile salt 
chelating resin-cholestyramine suggests that bile salts are responsible for pruritus. 
Painless jaundice, infact, is found only in minority of patients. Most of the 
patients present with painful jaundice. 
Patient will pass yellowish urine due to increased excretion of bilirubin and 
clay coloured stools due to the absence of stercobilin. 
Pain: 
50-80% of presenting symptom of periampullary cancer. abdominal pain is 
present less commonly in ampullary cancer than carcinoma Head. In majority of 
patients, pain of moderate intensity is present as a result of obstruction of either 
the biliary or the pancreatic duct. The more intense pain may be due to invasion of 
retropancreatic nerves as well as due to obstruction of the pancreatic duct. 
 
Weight loss 
In periampullary growth weight loss will be progressive. By the time the 
diagnosis is made, weight loss of more than 10 % of ideal body weight is 
common. There are several possible explanations for the weight loss. Decreased 
intake of food is the commonest cause due to pain associated with anorexia. The 
other causes are malabsorption and increased catabolic activity. 
Malena 
There may be malena due to bleeding from the tumor or due to infiltration 
of the duodenum, stomach, or colon. In some patients bleeding may be occult. 
Clay coloured stools are common and when mixed with blood it is called silvery 
or aluminium paint stool. 
Vomiting 
Nausea and vomiting due to duodenal obstruction, are usually late 
manifestations. 
Diabetes 
New onset diabetes is observed in 15 % to 20 % of patients with pancreatic 
cancer two years before diagnosis. 
Others 
Obstructions of pancreatic duct may result in malabsorption and 
steatorrhea. An unexplained attack of pancreatitis in an older patient may be due to 
periampullary growth. The other less common manifestation is superficial 
thrombophlebitis. 
PHYSICAL FINDINGS 
Gall bladder 
Although the gall bladder is frequently found distended at Laparotomy, it is 
palpated on clinical examination in about 30 %-50 % of patients with 
periampullary carcinoma. 
Courvoisier’s Law 
In obstruction of the common bile duct due to stone, distension of 
gallbladder seldom occurs; the organ usually is already shriveled. In obstruction 
from other causes, distention is common by comparison. 
The reason for this difference between the two common causes of 
obstructive Jaundice is two fold. First in patients with calculous obstruction, the 
gallbladder is commonly affected by cholecystitis with fibrosis and so it cannot 
readily distend. In patients with periampullary carcinoma, the gallbladder is 
usually normal and therefore it is distensible. 
Secondly in patients with stone in the duct the obstruction is usually 
incomplete so that the pressure in the ductal system does not rise as high as in 
malignant obstruction, where the obstruction is usually complete and continuous. 
Hepatomegaly 
 It is palpable in about 50 % of cases. It does not denote inoperability, since 
it may be due to biliary obstruction and not due to hepatic metastases. If there is a 
nodular liver with ascites, it indicates inoperability. Ascites is present in 25 % of 
cases. 
Splenomegaly 
This is due to splenic vein thrombosis and occurs in about 10 % of cases. 
Inoperable signs  
Patient with peritoneal spread may present with palpable mass, ascites, 
umblical nodule, blumer shelf and Virchow’s Node (consequence of tumor cell 
arriving via thoracic duct)  
  Few patients may present with pleural effusion, bone metastases. They 
indicate inoperability 
 
INVESTIGATIONS 
Laboratory investigations 
I. Urine examinations – To detect jaundice. 
1. Macroscopic – colour – It will be yellow or dark yellow in colour. 
2. Biochemical 
Bile salts, bile pigments – will be positive. 
Urobilinogen – will be negative. 
 
II. Motion examination 
1. Macroscopic – colour- clay coloured due to absence of stercobilin. 
Sticky, tarry malena stools due to bleeding. 
2. Occult blood – positive, if there is bleeding from periampullary growth. 
III. Blood investigations. 
1. Haemoglobin – may be low. 
2. Blood sugar – High if the patient is diabetic. 
3. Blood urea and creatinine may be elevated due to renal impairment in 
obstructive jaundice. 
4. Serum bilirubin – to confirm the hyperbilirubinemia. Normal – upto 1 
mg. At 2 mg, the tinge of jaundice appears, there will be conjugated 
hyperbilirubinemia. 
5. Serum Alkaline phosphate (ALP) Normal Level – 35 to 130 IU / L. It 
will be elevated in the obstructive jaundice. 
6. Serum Transaminases (ALT, AST). Normal Level – 5 to 40 IU/L. Mild 
to moderate elevation is seen in the obstructive jaundice. 
7. Prothrombin Time Normal – 12 to 16 seconds.It may be prolonged in 
the obstructive jaundice and correctable with administration of injection 
vitamin K. 
8. Serum proteins. Normal – 6.5 to 8 gm %. They may be decreased and 
reversal of albumin – globulin ratio may be seen. 
 
 
 
 
 
DUODENOSCOPY 
 This is the most useful investigation to diagnose the carcinoma of the 
ampulla of vater, with side viewing instrument, 
1. Growth can be seen in the ampulla. 
2. Biopsy can be taken. 
3. Assessment of duodenal obstruction due to duodenal growth or infiltration  
    of duodenum by carcinoma of head of pancreas. 
 
4. ERCP- Endoscopic retrograde cholangio pancreaticography   
 
1) Using the endoscopic approach ampullary and duodenal carcinoma    
     can be  visualized and biopsy can be taken. 
2) If not able to take biopsy, with brushing of   tumor, cytological  
     examination can be made. 
3) Abrupt tapering of both ducts (double duct sign) is highly suggestive   
    of  periampullary carcinoma. 
4)  A biliary stent can be placed through the obstructing lesion in the   
     bile duct by endoscopic approach to alleviate jaundice. 
5)  We can accurately stage the tumor by doing endoscopic    
ultrasonography. 
 
 
RADIOLOGICAL WORK UP. 
I Barium Meal 
1. In carcinoma of the head of pancreas, it shows widening of the C-loop of 
the duodenum. It is called as ‘pad’ sign. 
2. In carcinoma of the ampulla of vater, Reversed ‘3’ appearance can be seen. 
3. Delayed gastric emptying and duodenal obstruction can be diagnosed. 
 
Nowadays, barium meal is usually not done due to the advent of endoscopy 
and availability of other modalities of investigations like USG and CT scan. But if 
the patient is presenting with vomiting and OGD scopy showing no obstruction. 
we can still do Barium meal to detect delayed gastric emptying due to duodenal 
obstruction. 
 
II. Hypotonic duodenography. 
 A double lumen tube (Gastro duodenal tube-scott Harden) is passed into 
the duodenum. 20-40 ml of thin barium solution is passed through it. 4 mg of 
antrenyl was given intravenously to render the duodenum atonic, and air is 
insufflated. Then X-ray is taken. It gives a clear outline of the viscera. When 
carcinoma of head of pancreas has infiltrated the duodenal wall, it gives the 
appearance of Spiculation of rose thorn. 
 
 
III.ULTRASONOGRAPHY 
a. Transabdominal 
 This is a painless, harmless, non-invasive procedure which is relatively 
inexpensive and preferred investigation in jaundiced patients. It is widely available 
and entirely operator dependent with sensitivity of 80%-95%. 
 The findings are intra and extra hepatic biliary ductal dilatation, distended 
gallbladder, hypodense or isodense lesion in the head of pancreas, Secondary 
deposits in the parenchyma of liver and ascites. 
 
b. Endoscopic Ultrasonography (EUS) 
1) It employs a 7.5 – 12 MHZ transducer mounted on an endoscope to produce 
high resolution images. The pancreatic head and distal CBD are visualized 
from duodenum. 
2) Recommended only for patients in whom pancreatic mass is suspected but                           
can’t be confirmed by helical CT or ERCP. 
3) Useful in detecting small pancreatic lesions (<2cm) and also lymphnode and 
vascular involvement. 
4) Useful in evaluation of ampullary tumors with respect to invasion of duodenal 
wall, pancreas & vascular invasion & encasement. 
5) Experience with this technique, which is operator-dependent is still limited, 
precluding its widespread use. 
6) Normal pancreas is seen as having a homogenous echopattern slightly brighter 
than that of the liver. The features of the carcinoma pancreas are 
inhomogenous and echopoor pattern, irregular outer margins, and the presence 
of tumorous pseudopodia. 
 
c. Pancreatic duct Ultrasonography 
  With use of a small ultrasound transducer passed through the biopsy 
channel of duodenoscope and into pancreatic duct, the duct was evaluated. It is 
useful to differentiate Chronic pancreatitis from pancreatic carcinoma. 
 
IV. CT Scan 
 Dynamic contrast enhanced spiral CT Scan detect lesion about 2cm in size. 
1. It has an accuracy of 97% in detecting the presence of tumor. 
2. The CT Criteria of unresectability are local tumor extension beyond the 
confines of the normal gland, invasion of contiguous hollow or solid organs, 
circumferential or contiguous tumor involvement of major extrapancreatic arteries 
or/and veins, hepatic or lymph node metastases and ascites. 
3. Although, CT Scanning is a specific modiality for determination of 
unresectability for pancreatic carcinoma. It does not accurately identify patients 
with resectable lesion. 
4. In approximately 40% of cases, CT Scan evaluation alone under estimates the 
extent of lesion. 
 
V. MRI   
  Ultra fast MR imaging, including MR cholangiopancreatography, 
angiography, MR with Echoplanner imaging, may replace ERCP, in near future. 
 
VI. Laparoscopy 
This is an additional staging modality to evaluate periampullary patients 
before they are subjected to laparotomy. 
1) Can pick up small liver or peritoneal metastases, which are usually missed by 
CT Scan. 
2) Irrigation of peritoneal cavity can be performed and washings analysed 
cytologically for evidence of shed malignant cells. 
3) Palliative Stent can be placed in inoperable cases, as a therapeutic measure. 
4) Laparoscopy contact USG is the newer diagnostic method used to decide the 
diagnostic dilemma cases for surgery. 
5) Combination of dynamic CT and Laparoscopic staging has an accuracy of  
      >90% in predicting resectability.  
VII. Biopsy and FNCA 
 Diagnosis is confirmed by taking biopsy from the periampullary growth via 
an endoscope. In a palpable mass, we can do CT or EUS guided FNAC. But 
FNAC is not used for potentially resectable tumors, because negative result does 
not rule out carcinoma and the fear of shedding of the tumor, either along the 
needle tract or into the peritoneal cavity. 
 For resectable lesion, Preoperative FNAC is of no additional value except 
when preoperative neoadjuvant chemo or radiation is contemplated. 
 For irresectable cases, percutaneous FNAC has a role in proving diagnosis 
before consideration of Palliative chemoRT. 
VIII. Estimation of CA – 19-9. 
• Normal Value < 35 U/ml 
• In Pancreatic Cancer > 100 U/L (in 73% of patients) 
It has a sensitivity and specificity approaching 90% for tumors arising in the 
pancreas. It is useful for prognosis and follow up surveillance. 
 
IX. Angiography 
 Preoperative visceral angiography with arterial injection of celiac & SMA 
with venous phase studies provides the best demonstration of vascular anatomy, 
major vessel encasement or occlusion. It will also detect anatomical variations, 
such as a replaced right hepatic artery or Atherosclerotic stenosis or celiac axis. 
 
PREOPERATIVE STAGING 
Preoperative staging is more useful for pancreatic tumors than for other 
forms of periampullary cancer, since resectability for the latter lesions is usually 
significantly higher at the time of presentation than it is for pancreatic cancer. In 
many patients, dynamic spiral CT with oral and intravenous contrast will provide 
all the information necessary by demonstrating liver metastases or major vascular 
invasion. 
 
 Preoperative visceral angiography with arterial injection of the celiac and 
superior mesenteric arteries with venous phase studies provides the best 
demonstration of vascular anatomy and major vessel encasement or occlusion. 
 
 Visceral angiography also will detect anatomic variations, such as a 
replaced right hepatic artery or atherosclerotic stenosis or occlusion of the celiac 
axis that may alter operative management. Angiography is indicated, however, in 
these patients to rule out involvement of the superior mesenteric and portal vein 
and/or celiac axis. 
 
 Endoscopic ultrasonography is to detect small pancreatic lesions (<2 cm) 
and also lymph node and vascular involvement. This technique is also particularly 
useful in the evaluation of ampullary tumors with respect to invasion of the 
duodenal wall and pancreas. 
 
 A recent study in preoperative patients suggested that endoscopic 
ultrasound examination was superior to conventional sonography. 
 
 Liver metastases and peritoneal implants are the common sites of spread of 
periampullary carcinoma. Once distant metastasis present, survival is so limited 
that a conservative approach is indicated. 
 The technique of diagnostic laproscopy, before the patient is subjected to 
laparotomy, has been used by several groups as an additional staging modality for 
the evaluation of patients with pancreatic and periampullary malignancies. 
 
 The information gained from preoperative staging provides a basis for 
planning for each individual patient. If preoperative staging with CT, angiography, 
and laparoscopy is normal, resectability rates may approach 90 % for tumors of 
the head of the pancreas. Preoperative staging, therefore, results in a considerable 
improvement from previous resectability rates of less than 25 %, and thus 
eliminates the need for an unnecessary operation in a large number of patients. 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT OF PERIAMPULLARY CARCINOMA 
 Treatment of periampullary carcinoma depends upon the stage at 
presentation and presence or absence of comorbid medical conditions influencing 
treatment modalities.  
 
 Surgical resection of the tumor currently provides the only opportunity for 
cure in these patients if the tumor is resectable. 
 
 If the patient is presents with unresectable tumor with jaundice, with or 
without hepatic secondaries, we can do palliative biliary enteric and Gastrojejunal 
anastomosis, if there is no other comorbid medical diseases contraindicating the 
surgery. If the patient is medically unfit for surgery an endoscopic stenting may be 
done. 
 
 A patient with widespread metastatic disease, does not need any type of 
surgery because median survival is short. In these patients, palliative endoscopic 
biliary stenting can be done to relieve the jaundice. If the patient has unresectable 
tumor with severe pain, celiac axis block, either percutaneously or during 
laparotomy, can be done. 
 
PREOPERATIVE PREPARATION 
 
 If the surgery is planned, whether it is curative or palliative, it is important 
to optimise cardiac, pulmonary, and renal function preoperatively, as in all patients 
about to undergo major surgery. 
 Because obstructive jaundice can cause defects in hepatic, and renal 
function, it is important to correct all these abnormalities preoperatively if they are 
present. 
1. Correction of anemia with preoperative blood transfusion. 
2. All patients are adequately nourished with high allowance of carbohydrate 
diet. 
3. If there is dehydration due to vomiting in patients with duodenal 
obstruction, It is corrected by administration of intravenous fluids. 
4. If there is duodenal obstruction, stomach wash should be given with normal 
saline. 
5. Correction of disorders of coagulation 
The coagulation defect encountered in patients with obstructive jaundice is 
prolonged prothrombin time, resulting from deficiency of Vitamin K 
dependent clotting factors due to malabsorption of this vitamin. 
It is corrected by administration of intramuscular injection of 
phytomenadione (Vit K) for 1-3 days or with blood and fresh frozen plasma 
transfusion. 
6. Prevention of renal failure 
Cholemia and liver damage per se are associated with adverse effects on renal 
structure and function, and on circulatory haemostasis and on the integrity of the 
gastrointestinal barrier. Even in the absence of infection, endotoxemia is 
frequently present in jaundiced patient where it results from the absorption of 
endotoxin produced by the intestinal microflora. Therefore, the patients with 
obstructive jaundice have an increased risk of Postoperative acute renal failure. 
 Two pints of 10% Dextrose infusion given every day prior to surgery 
minimum for 3 days. 
 Mannitol may be given on the day before, during and the day after surgery. 
It protects the kidneys by acting as an osmotic diuretic and by increasing 
the renal perfusion.  
 Oral Lactulose to reduce the intestinal absorption of endotoxins from the 
intestinal microflora. 
 All patients undergoing surgery should be catheterized and the urint output 
measured hourly. Further administration of diuretic is indicated if the urine 
output falls consistently below 40ml/hr. 
 
 
 
 
WHIPPLE’S PANCREATICODUODENECTOMY 
 
Step 1 
• upper midline/subcostal  incision . 
• inspect liver & peritoneal surfaces. Biopsy /frozen section of suspected area  
• regional nodes are inspected ( periaortic lympnodes of the coeliac axis 
indicates tumor is beyond the limits of resection) 
• once  distant metastsis  are ruled out, assess  local resctability. 
• positive nodes within the planned field of resction are not considered a 
contraindication to curative surgery 
 
Step 2 
The hepatic flexure of colon is mobilized from its retroperitoneal 
attachment, giving access to the 3 & 4 portions of the duodenum. Extensive 
mobilization of right colon & small bowel mesentry (Cattell-Braasch maneuver) 
is unnecessary except for lesions involving the fourth portion of duodenum, or for 
the approach to mobilization and resection of segment of SMV.  The duodenum 
and head of pancreas are separated from the retroperitoneal bed medially past 
aorta and distally to the ligament of Treitz. 
 
 
Step 3 
   The gallblader is removed and the bileduct is dissected free from adjacent 
portal structures and divided above the entry to cystic duct across the common 
hepatic duct (because of tendency of periampullary cancers to infiltrate cephlad 
along the submucosal lymphatic channels of bile duct).  
  The distal bileduct orifice is sutured to minimize spillage of tumor cells, but 
no clamp is used on the proximal bile duct, to avoid trauma to the duct. If evidence 
of unresectable cancer is discovered later in the operation, the proxial duct is used 
for palliative bypass. The tissues lateral to portal vein are carefully separated and 
divided, with additional care taken to be sure that a replaced aberrant right hepatic 
artery of the SMA is not included. 
 Step 4 
The portal dissection is continued down along the anterior aspect of the 
portal vein, beginning with development of the tunnel in front of the vein and 
behind the neck of pancreas. Division of right gastric artery & gastroduodenal 
artery enlarges this window. Division of these vessels facilitates dissection of 
portal vein behind pancreas. The middle colic vein and gastroepiploic vein can be 
traced down to SMV for rapid identification. (Periampullary tumors are much 
more likely to involve the lateral & posterior aspect of portal /mesenteric vein) 
 
 
 
Step 5  
After dividing the left gastric & gastroepiploic vessels at the gastric wall, 
the stomach is divided across the proximal antrum. Alternatively, the duodenum   
2 cm past the pylorus may be divided  
 
Step 6  
After the pancreatic neck has been carefully dissected from anterior surface 
of portal-superior mesenteric vein, a penrose drain is placed behind the neck to 
elevate and protect the portal vein during division. Four hemostatic sutures are 
placed on either side of the transection line. The pancreas is now ready to be 
divided with electrocautery. 
 
Step 7 
Ligament of Treitz is taken down in its entirety and the jejunum is divided 
6 to 10 cm past the ligament. The jejunal vascular branches are divided at the 
bowel wall along the inner curvature. 
 
Step 8  
The final step in removal of the specimen is to divide the venous tributaries 
of SMPV and dissect along the lateral margin of the SMA, taking both arterial 
branches & the periarterial soft tissues, which include both lymphatics & nerve 
plexuses that can contain tumor.  
Step 9 
Pancreaticojejunostomy is performed first. The anastomosis is created in 
two layers, end - to - side, duct- to- mucosa, using an outer row of interrupted, 
non-absorbable 3-0 sutures that includes most of the cut surfaces of pancreas & an 
inner row of 4-0 interrupted synthetic absorbable sutures duct- to –mucosa.    
When the pancreatic duct is small or normal in size, a 5F feeding tube is placed in 
the pancreatic duct and brought out through the jejunum. 
Step 10  
10 cms distal to the pancreatic anastamosis, an end –to- side 
hepaticojejunostomy is made with a single layer of interrupted closely spaced 
synthetic absorbable sutures. A small (8 to 12 F) catheter can be left through the 
anastamosis & brought out distally through jejunum. 
Step 11  
After fixing the jejunal loop to the transverse meso colon with interrupted 
nonabsorbable sutures, GI continuity is restored with a retro-colic Hofmeister-type 
Billroth II gastrojejunostomy. This anastamosis is made with running absorbable 
sutures as an inner layer and interrupted nonabsorbable sutures as an outer layer. 
Step 12  
  Soft closed-suction drains are placed in the right upper quadrant, anterior 
and posterior to biliary and pancreatic anastamoses. These are brought out through 
separate incisions in the right side of the abdomen. The abdominal wall is closed 
in layers. 
POST OPERATIVE CARE 
 The nasogastric tube is discontinued on postoperative day 1 and clear 
liquids may be allowed on day 2. The diet is advanced to low-fat soft solids in 
frequent small feedings as tolerated. Blood glucose should be monitored and 
diabetes treated as appropriate. The concentration of amylase with closed- suction 
drainage is measured on day 5 or 6 when the patient is eating. If there are no 
indications of an anastomotic leak, the drains are removed on the sixth and seventh 
days. The pancreatic (and biliary) stents are removed at the post-operative visit, 
generally at 2 to 3 weeks.  
 
Pancreatic leak / fistula remain the most common serious complication of 
this operation. The mainstay of treatment is complete drainage of pancreatic leaks, 
either by closed-suction drains placed at operation or by percutaneously placed 
catheters if leak appears is delayed. The catheters should be left in place long 
enough to ensure formation of a secure tract and then withdrawn in segments to 
allow the tract to close behind as drainage closes. In the case of low-volume 
fistulas (less than 200 ml per day), patients may eat and be discharged to home. 
High output fistulas may require a more aggressive approach with fasting, 
maintenance of fluid and electrolyte balance, and parenteral nutrition. Octreotide 
200 units subcutaneously three times a day has been used as an adjunct to reduce 
fistula volume, but there is no clear evidence that closure is accelerated. 
 In the event of delayed gastric emptying for more than 7 to 10 days, a 
gastrografin contrast upper GI study should be performed to rule out mechanical 
obstruction. In most cases the condition resolves spontaneously, although the 
gastroparesis can persist as long as 3 to 4 weeks. Management consists of support. 
 
PALLIATION OF OBSTRUCTIVE JAUNDICE-  
Options for establishing biliary decompression are divided into endoscopic, 
radiologic and surgical approaches. Patients with histologically proven 
unresectable disease are most commonly treated by endoscopic or radiologic 
biliary stent placement. The sequence of palliative intervention is determined by 
the method used for cancer staging: laparotomy versus laparoscopy.   
For patients undergoing laparotomy, surgical bypass is a reasonable option 
in the presence of obstructive jaundice, and the feasibility of the procedure should 
be guided by the findings at surgery; prophylactic bypass in these patients is 
controversial but should be tailored to an individual patient’s needs.  
For patients undergoing laparoscopy, biliary decompression endoscopic 
stent placement is recommended; if not successful or unavailable, then the 
radiologic PTH stent placement should be performed to avoid laparotomy.  
In patients who develop recurrent obstructive jaundice following failure of 
the initial stent or because of progressive tumor radiologic PTH placement of 
expandable metallic wall stents under imaging control may then be indicated. 
Palliation of gastric outlet obstruction 
The management of pancreatic cancer patients with the potential to develop 
gastric outlet obstruction (reportedly 3%—9%) is predicated on the initial surgical 
staging technique (laparotomy versus laparoscopy).  
Patients with equivocal or potentially resectable disease, who undergo 
laparotomy, can be assessed for duodenal involvement or impending obstruction 
from the tumor during the surgery. Guided by the operative assessment, 
gastrojejunostomy can be performed effectively. Routine prophylactic gastric 
bypass in staging laparotomy has been historically advocated; however, the need 
for the procedure should be based on the individual patient’s needs.  
Patients with histologically confirmed unresectable disease and those 
undergoing staging laparoscopy rather than laparotomy for equivocal or 
potentially resectable pancreatic cancer are reasonably managed without 
prophylactic gastric bypass. If the patient develops subsequent obstruction, then 
gastric decompression can be achieved by several different methods, guided by the 
individual patient’s condition.  
Patients with good performance status, who are expected to have an 
extended survival, should undergo gastric bypass, preferably laparoscopically, or 
by laparotomy. For patients developing gastric outlet obstruction as a near-
terminal event, then endoscopic gastrostomy tube or expandable duodenal stent 
placement should be considered. 
 
Palliation of pain 
Standard narcotic analgesics are inadequate for most patients with 
pancreatic malignancy. Percutaneous celiac blockade for patients with 
histologically proven unresectable disease, who do not undergo laparotomy, is a 
logical approach (those undergoing laparotomy should be considered for 
intraopetative celiac blockade). Patients who obtain only short-term analgesia or 
fail to achieve pain relief from the percutaneous or laparotomy approaches should 
be considered on an individual basis for video-assisted thoracoscopic nerve 
transection 
 
NEOADJUVANT AND ADJUVANT THERAPY 
 Adjuvant chemoradiation therapy generally comprises external beam 
radiation therapy. 
 
 The theoretical advantages of neoadjuvant chemotherapy for patients with 
resectable pancreatic cancer are (1) it may be more effective to give radiation in 
well- vascularized tissues. (2) Previously unresectable tumors may become 
resectable, and (3) it may improve patient selection, preventing unnecessary 
laparotomies in patients with evidence of disease progression on neoadjuvant 
therapy (which occurs in approximately 20 % of patients). Despite these theoretic 
advantages, however, neoadjuvant therapy has not been shown to be superior to 
adjuvant therapy. 
 
 Adjuvant intraoperative electron beam radiation therapy (IORT), which 
delivers a single dose of 10 to 20 grays to the tumor bed at the time of resection, 
has therefore been used, alone or in combination with standard chemoradiation 
protocols to improve local control. In patients receiving neoadjuvant or adjuvant 
chemoradiation, tumor recurrence patterns change from locoregional failures  to 
systemic failures, with liver metastases becoming the predominant site of 
metastasis. 
 
Thus more effective systemic agents are needed. One such potential agent 
is gemcitabine (2’ – deoxy-2’2’-difluorocytidine, Gemzar), a deoxycytidine 
analog capable of inhibiting DNA replication and repair. 
 Gemcitabine is also a potent radiation sensitizer and is being combined 
with EBRT using a variety of treatment schedules in patients with advanced 
pancreatic cancer.  
 
 
 
 
PREDICTORS OF SURVIVAL AMONG 
PERIAMPULLARY CANCERS 
Survival Differences versus Cancer Stage 
Local Growth Pattern 
Early vs Late Jaundice 
 Patients with cancers directly involving the distal bile duct should present 
with jaundice at an earlier stage of disease. Current data suggest that most 
ampullary, duodenal, and distal bile duct tumors present without lymph node 
metastases, and consequently when resected are associated with a better prognosis 
than pancreatic cancer. Although bile duct cancers should present early and should 
be associated with a prognosis equivalent to ampullary cancers, the fact that 
survival is not equivalent suggests that other tumor subtype factors are involved. 
Clearly, the T stage of pancreatic cancer that obstructs the bile duct by extension 
from the pancreatic duct with encasement or invasion must be more advanced than 
the other periampullary cancers. 
Factors 
Focal growth patterns of the primary periampullary cancers likely 
contribute to outcome. Although initially all periampullary cancers arise 
intraluminally from mucosa, subsequent invasion of duct or gut wall carries 
different implications. 
Intraluminal Growth  
Biologic behavior among periampullary cancers is also manifested in their 
direction of growth. Intraluminal growth is present in 40% of ampullary cancers 
but in only 2% of pancreatic cancers and is followed by extraductal invasion in 
60% of the ampullary cancers and 98% of the pancreatic cancers. Adjacent tissue 
invasion represents advanced T stage of disease, and therefore, a poorer prognosis 
with an increased rate of invasion of lymphatic, venous, and perineural structures.  
 
When an nonpancreatic periampullary cancer invades the pancreatic 
parenchyma, the prognosis worsens (similar to the pancreatic counterpart), and the 
frequency of lymphatic involvement increases significantly. Invasion of ampullary 
cancers into the duodenal wall does not have the same adverse impact as does 
pancreatic invasion. Clearly, pancreatic invasion or origin portends a poor 
prognosis. Similar findings for the relationship of T stage for duodenal cancers 
and prognosis have been reported. 
  
 
 
 
Lymphatic and Neural Spread 
Lymphatic Spread. Lymphatic metastases represent an advanced disease 
stage. In fact, some authors maintain that lymphatic invasion is equivalent to 
established lymphatic metastases. Pancreatic cancers present with lymph node 
metastases in 56% to 79% of patients, ampullary cancers are associated with 
lymphatic metastases in 30% to 50%, and bile duct cancers in  56% to 69%. The 
frequency of lymph node metastases is significantly increased when nonpancreatic 
periampullary cancers invade the pancreas, which is especially reflected in para-
aortic lymph node metastases. 
Ampullary tumors often have limited nodal involvement. These cancers 
usually involve the posterior pancreatoduodenal nodes (“first echelon”) and 
seldom the nodes located to the left of the superior mesenteric artery and the celiac 
ganglion. In contrast, the nodal involvement in pancreatic cancer is more extensive 
and clearly involves both the above nodal groups. Shirai et al showed an increased 
survival after pancreaticoduodenectoimy and radical lymphadenectomy in 
ampullary tumors, which supports further evaluation of this aggressive approach 
even in the presence of lymphatic spread. 
Duodenal tumors behave biologically differently than pancreatic cancers. 
There is 36% to 47% incidence of positive lymph nodes in pancreaticoduodenec -
tomy specimens. Despite this frequency of nodal involvement, however, 5-year 
survival rate approaches 40% to 50%. In contrast, the presence of positive lymph 
nodes in patients with pancreatic cancer is associated with a 5-year survival of 
only 5% These findings justify a role for aggressive resection in duodenal and 
ampullary cancers, even in the presence of positive lymph nodes.  
Perineural Invasion. Perineural invasion, especially extrapancreatically, is 
an important prognostic factor associated with pancreatobiliary tract cancer and 
generally denotes a poor prognosis. Most patients with pancreatic carcinoma have 
perineural invasion (concomitantly with lymphatic vessel invasion). This feature 
of pancreatic cancer may contribute to the high incidence of local recurrence, 
especially retroperitoneally. In contrast, perineural invasion occurs in only 5% to 
17% of patients with ampullary cancers, which has a lower local recurrence rate 
after resection. Interestingly, when perineural invasion is present with 
periampullary cancers, the prognosis is similar to pancreatic cancers. Finally,  
although bile duct cancers are associated with a high (86%) incidence of 
perineural invasion, correlation with local recurrence has not been established 
because the frequency of positive post-resection margins is a confounding factor. 
Molecular Concepts and Clinical Correlation  
Duodenal and ampullary tumors have the best prognosis among 
periampullary cancers. They are similar in their genesis; some ampullary cancers 
may arise from the duodenal type of epithelium and hence they share some of the 
steps of the molecular development model. This fact is evidenced in the data by 
Zhu et al, where some genes, tumor markers, and expression of growth factors are 
present in similar percentage in both cancers. Other genetic alterations, like the 
mutation of the K-ras oncogene, are almost exclusive to pancreatic cancers among 
the periampullary cancers. Pancreatic cancers also express the receptor for EGFR, 
which is not expressed by other periampullary cancers and is associated with a 
much worse prognosis. Finally, some histologic similarities were found between 
bile duct and pancreatic cancers, traditionally the ones with the worst outcome. 
Overall, it is impossible to point out a specific factor to explain the different 
outcomes of these cancers. The combinations of these features will ultimately 
determine the biologic behavior of each cancer. 
 
Stage at Initial Presentation. Size of primary tumor, tumor histologic 
differentiation, lymph node status, and resection margin status are very important 
when defining poor prognostic factors. At presentation, pancreatic cancers have 
the highest frequency of these factors when compared with nonpancreatic 
periampullary cancers. 
 
A higher incidence of positive margins after apparent curative resection in 
pancreatic cancer is a reflection of its usual early perineural invasion and accounts 
for its higher locoregional recurrence. The clinical correlation of decreased 
survival in pancreatic cancer is obvious after analysing the data. 
INNOVATIVE STRATEGIES 
 
Significant advances in understanding basic immunology have renewed 
interest in using immunotherapy to treat pancreatic cancer. Cancer 
immunotherapy, including humanized Monoclonal Antibodies, cytokines, and 
potent vaccine strategies, has been successful in animal models and is being 
evaluated in clinical trials.  
 
Gene therapy is also being explored using methods to inactivate oncogenes, 
replace defective tumor suppressor genes, confer enhanced chemosensitivity to 
tumor cells, and increase immunogenicity of tumor cells.  
 
Angiogenesis, an essential step in the growth and metastasis of pancreatic 
cancer, has been targeted by many antiangiogenic agents. Several clinical trials 
have been initiated to evaluate the role of these innovative strategies in patients 
with pancreatic cancer with increasingly sophisticated correlative studies to learn 
more about the mechanisms of tumor rejection with these agents.  
 
The rapid translation of basic science discoveries to clinical trials should 
result in the development of new effective treatments for patients with pancreatic 
cancer. 
KEY POINTS 
 
Most of the Literatures support the clinical impression that periampullary 
cancers vary in outcome after resection.  
Overall survival after pancreaticoduodenectomy is greatest for patients with 
ampullary and duodenal cancers, intermediate for patients with bile duct cancer, 
and least for patients with pancreatic cancer.  
Moreover, survival for each tumor stage is greater for nonpancreatic 
periampullary cancers than for pancreatic cancers. Invasion of the pancreas by 
nonpancreatic periampullary cancers is a major factor adversely affecting survival.  
Recent data suggest that inherent differences in tumor biology rather than 
embryologic, anatomic, or histologic factors probably account for these 
differences in survival.  
Finally, although pancreaticoduodenectomy remains the procedure of 
choice for resectable periampullary cancers, further increases in survival will 
likely evolve through more effective neoadjuvant or adjuvant therapies rather than 
modification in the surgical approach. 
 
  
MATERIALS AND METHODS 
 
This work includes the study of 26 patients, with a diagnosis of 
periampullary carcinoma, who were admitted in the Thanjavur Medical College 
Hospital, Thanjavur, between June 2004 and October 2006. 
The methods include obtaining the important informations from the 
patients, thorough clinical examination and doing the investigations whatever 
necessary to aid the diagnosis and resectability. All the informations were entered 
in a proforma specially designed for this study. 
The patient’s age, sex, symptoms and its duration were obtained. Personal 
history like smoking habits, alcohol consumption and their duration were noted. 
History of recent onset of diabetes mellitus, if present was noted. 
 In all these patients, nourishment and presence of jaundice were noted. 
Abdomen was examined to detect hepatomegaly, palpable gallbladder, ascites and 
mass. Rectal examination was done to find out rectovesical or recto vaginal 
deposits . 
 Respiratory system was examined to find out the pleural effusion. 
Enlargement of left supraclavicular node (virchow ‘s node) and umbilical nodule 
(sister mary joseph’s nodule )   if present, were  noted. 
 Basic investigations like urine examination, Hb% estimation, Blood sugar 
and renal parameters like urea and creatinine were done in all these patients.  liver 
function test like serum bilirubin, serum proteins, clotting time, serum alkaline 
phosphatase, liver enzymes and prothrombin time were also done. 
 Upper gastrointestinal endoscopy was done in all the patients and biopsy 
was taken if the growth was seen. 
 Initially, ultrasonogram abdomen was done in all patients, then CT Scan 
abdomen was done to confirm the diagnosis and to know the resectability. X-ray 
chest was taken to know the pulmonary metastases and pleural effusion. 
 Based on above investigations treatment was planned accordingly. If the 
patient was fit for surgery, either curative resection or palliative bypass procedure 
was done.  If not, the patient was managed conservatively or referred to higher 
institutions for palliative endoscopic stenting. 
 Postoperative complications were noted and managed accordingly. Most of 
the patients who were operated were followed up in our review clinic. 
 
 
 
 
 
 
 
 OBSERVATION AND RESULTS 
 
1. Incidence 
 Total of 26 cases were admitted in the period between June 04 to October 
06, accounting for 1.15 % of all cancers, in TMCH (Total cancer case in this 
period - 2260)  
 
 Out of 26 cases 15 cases were carcinoma head of pancreas, accounting for 
the 58 % of total periampullary carcinoma. 
 7 cases (27 %) were carcinoma of the ampulla of vater  
2 cases (8 %) of carcinoma of distal CBD  
2 cases (8 %) of duodenal carcinoma 
 
2. Age incidence 
 All the cases were in the age group of 31-70. Among this 17 cases (65 %) 
were in the age group of 40-59, 2 cases (8 %) were in the age group of 30-39 and 5 
cases (19 %) in the age group of 60-69. 
 
3. Sex Incidence: 
 There were 17 male patients (65 %) and 9 female patients (35 %) with a 
male: female ratio of 1.8 : 1 
4. Symptomatology: 
    Pain 
 19 patients (73 %) were admitted with abdominal pain with a duration of    
1 week to 4 months. In most of the patients the pain was in the epigastrium and 
mild to moderate in intensity. 
 
Jaundice 
22 patients (85%) were admitted with jaundice with a duration of 15 days 
to 7 months. Most of the patients with jaundice also had generalized pruritius and 
were passing clay coloured stools. 
 14 Patients (54 %) were admitted with weight loss. 
 12 patients (46 %) had vomiting 
 11 patients (42 %) were admitted with upper GI Bleed. 
 2 patients (8 %) had abdominal mass at presentation. 
 
5. Smoking  
 14 patients (54 %) were smokers for more than 15 years of duration. 
 
6. Alcohol Consumption 
 Only 4 patients (15 %) were chronic alcoholics for more than 15 years of 
duration. 
 
7. Diabetes Mellitus 
 In this study 4 patients (15 %) had diabetes mellitus. Among this 2 patients 
(8 %) were admitted with recent onset of diabetes mellitus. Another 2 patients      
(8 %) were found to be diabetic which was confirmed by blood sugar levels. 
 
8.Palpable Gallbladder 
 Only in 11 cases ( 42 %) gallbladder was palpable, Although distended 
gallbladder was detected by ultrasonogram in all cases (19 cases) which was later 
confirmed at laprotomy. 
 
9.Hepatomegaly 
 Enlargement of liver was present in 19 cases (73 %) clinically. Among this 
26 % had smooth enlargement, remaining 47 % cases had nodular enlargement. 
On USG, cases had liver secondaries in the latter group. 
 
EXTENT OF DISEASE: 
 Extent of disease was evaluated by ultrasonogram, CT scan abdomen, Xray 
chest with clinical examination. 
 12 patients (46 %) had hepatic secondaries. 
 7 patients (27 %) had ascites. 
 2 patients (8 %) had pleural effusion  
 2 patients (8 %) had enlargement of left supra clavicualr lymph node. 
 8 patients (31 %) had duodenal obstruction. 
 CT SCAN ABDOMEN IN EVALUATION 
 Resectability at computed tomography was correlated with local surgical 
resectability in Carcinoma head of pancreas. Among the 14 patients who had 
resectable tumor after CT Scan evaluation, 6 patients had nonresectable tumor  at 
laparotomy. 
 All the patients who had nonresectable tumor after CT scan evaluation, had 
irresectable tumor at laparotomy also. 
 
SIZE OF THE TUMOR  
The size of the tumors ranged from 2cms to 10cms, average being 5 cms.        
No patients with tumor smaller than 2 cms was seen in our study. The size of the 
tumor in a resectable carcinoma was 2.5cms – 3.5cms. No patients with tumor size 
of, more than 4cms had curative resection. 
 
MANAGEMENT 
After preoperative evaluation, 14cases were posted for surgery with 
curative intent, but resection was possible in only 8 cases. The remaining 6 cases 
had palliative surgery. 5 cases were evaluated to be unresectable preoperatively, 
and since their general condition was fit for surgery, Palliative bypass procedures 
were planned and done. Seven patients were not fit for any surgical intervention, 
So they were managed conservatively. 
 
CARCINOMA HEAD OF PANCREAS 
 
Among the 15 cases of carcinoma head of pancreas, 9 cases found to be 
resectable by preoperative evaluation, so posted for curative surgery. But on 
laparotomy, only 2 patients had resectable tumor and they underwent 
pancreaticoduodenectomy. Since, the other 4 patients were found to have local 
infiltration into vascular structures& fixity (unresectable), hence  palliative bypass 
procedure done. 
 Liver metastases were detected, in the remaining 3 patients, and since these 
patients were fit for surgery, palliative bypass procedure was done. 
 Totally 7 patients (46.7%) underwent palliative bypass procedures. Among 
these 7 patients, 3 patients (20%) underwent  choledochojejunostomy with 
jejunojejunostomy and  4 patients (27%) underwent  Biliary bypass and 
Gastroenteric bypass.  
 4 patients (26.66%) presented with advanced stage of disease .so, they were 
not fit for any surgical intervention. Two cases (13.33 %) referred for stenting. 
 
CARCINOMA OF AMPULLA OF VATER 
Among the 7 cases, 5 cases (71.42%) underwent curative resection. 2 
patients (28.57%) underwent palliative biliary bypass due to presence of hepatic 
secondaries. 
 
CARCINOMA OF DISTAL CBD 
 
Since both the patients had liver metastases but they were fit for surgery, 
palliative biliary and Gastroenteric bypass were done. 
 
Duodenal Carcinoma 
 
 Among the admitted 2 patients, one patient underwent curative surgery, the 
other patient was medically not fit for any surgical intervention. 
 
MANAGEMENT SUMMARY 
 
Total patients were 26, Among these 26 patients, 8 patients(30.76%) 
underwent curative surgery. 11 patients(42.3%) underwent palliative bypass 
procedures. Among these, 5 patients (19.23%) underwent biliary bypass only and 
6 patients (23.07%) underwent  both  biliary  bypass and gastroenteric bypass. 
7 patients (26.9%) had no surgical treatment. Among these 2 patients(7.69%) were 
referred for palliative endoscopic stenting and 5 patients (19.23%) had no surgical 
intervention due to poor general condition and also due to presence of an advanced 
disease. 
 
 
 
POSTOPERATIVE MANAGEMENT  
Curative cases:  
 Among 8 patients who had curative resection, 2 patients(25%) died 
postoperatively. Death were due to uncontrollable  postoperative shock and 
myocardial infarction. 
 Among the remaining 6 cases, 3 cases had pancreatic leak(37.5%) and 2 
patients had minor wound infection(33%) which were managed conservatively. 
Palliative cases: 
 Among the 11 patients who underwent bypass procedures, 3 patients 
(27.3%) had wound infection, one patient (9.1%) had delayed gastric emptying 
and there was nil mortality. 
 
FOLLOW UP 
 Out of 19 patients who underwent surgery, 2 patients died postoperatively. 
In remaining 17 patients, 8 patients turned up for review.   
Curative cases: 
 Among the 6 curative patients, 2 patients were lost for follow up, the 
remaining 4 patients were periodically evaluated for local recurrence and or 
metastasis of disease. 
Median survival of patients with pancreatic periampullary tumors are 9 to 
12 months and non-pancreatic periampullary tumors are12 to 18 months. 
 
Palliative cases: 
 Among the 11 palliative patients, 7 cases were lost follow up.  
 2 patients who underwent only biliary bypass were admitted with gastric outlet 
obstruction after 6 months and underwent gastrojejunostomy. 
            This group of patients have a median survival of 6 to 9 months.  
 
Conservative cases: 
Patients   managed conservatively generally had an even shorter survival, 
less than 6 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Incidence 
 In both men and women, periampullary carcinoma represents 3 % of all 
cancers in the western world. India has the lowest incidence in the world (Muir C 
et al) 
 In study by Shantha V et al, the periampullary carcinoma accounted for 
1.14 % of all carcinoma in men and women. 
 In our study, it is 1.15 % of all carcinomas. This may be due to low intake 
of fat, protein and low incidence of smoking in our country. 
 In a study by Lyon JL et al, there is a correlation between per capita 
saturated and total saturated fat intake and an increased risk of pancreatic 
carcinoma. 
 
Age 
 The incidence is peak in the age group of 60 – 80, with more than 80 % of 
cases in the above age group (Gordis L et al and Morgan RGH et al). 
 In a study by Shantha V et al, 78.95 % of patients were in the age group of 
40-69. Where as in our study, 84.61% patients were belongs to 40 to 69 age group. 
 In our population, the incidence of carcinoma was observed 2 decades 
earlier than western population. 
 
Sex 
 In a study Akoik et al and Muir C et al, the male / female ratio was between 
1.5:1 to 2:1. 
 In a study by Shantha V et al, the male / female ratio was 1.92 to 1. In  our 
study, it was 1.8:1 
 
SYMPTOMATOLOGY 
 The three main symptoms of periampullary carcinomas are pain, loss of 
weight and jaundice (Sir David C et al). 
 
Jaundice 
 Since, the periampullary carcinoma, by definition, arises near the distal 
biliary tree, obstructive jaundice is the hall mark of presentation (Michael J.Zinner 
et.al). 
 
 In University of Mannheim study, 82 % of patients were presented with 
jaundice. In our study, it was 84.61 %. 
 
 The common misconception is that periampullary carcinoma is associated 
with painless Jaundice, when, infact, the overwhelming majority of patients had 
pain (JAMES.BARKIN et.al & A CUSCHIERI et al.) in our study 73.07 % 
patients had painful jaundice. 
Pain 
 In University of Mannheim study, the pain was present in 75 % of patients. 
In our study, it was 73.07 %. 
 In the study by Ridder GJ et al, severe pain, that is due to infiltration of 
retroperitoneum, indicated the incurability. 
 In our study, the patients admitted with severe pain had advanced disease. 
No patient with resectable tumor had any severe pain. 
 
Weight loss: 
 According to pereZ MM et al and petrek JA et al, if the patient is presenting 
with rapid weight loss, the tumor is less likely to be resectable. In our study, 14 
patients with weight loss except one had irresectable tumor at presentation. 
 
Vomiting: 
 Vomiting was present in 29 % of patients in University of Mannheim study. 
In our study, it was 46.15 % of which 31 % of due to duodenal obstruction. 
 
Diabetes mellitus: 
 In a study by Rosa JA et al the newer onset of diabetes observed in 15 % - 
20% of patients with pancreatic cancer , two years before tumor  diagnosis.was 
made. 
 In a study by Guillo L et al, the prevalence of diabetes in pancreatic 
carcinoma is significantly greater than control. Glucose intolerance develops 6-12 
months before diagnosis in 10-15 % of patients (Murr MM et al). 
 
 In our study, the prevalence of diabetes mellitus was 15.38 %. So diabetes 
mellitus of recent onset in non-obese individuals should raise the suspicion of 
pancreatic cancer and investigation should be done. 
 
Smoking: 
 Smoking is the best established risk factor for pancreatic carcinoma 
(Kauppine T et al, Gold EB et al). There ia a dose relationship to the number of 
cigarettes smoked and the occurrence of carcinoma (Ablgren JD et al). In our 
study 54 % of patients were smokers for more than 15 years duration. 
 
 The study of Talamini G et al showed that 64 % of pancreatic carcinoma 
patients were smokers compared to 35 % of control. 
 
Alcoholism 
 A cohort study by Zheng W et al, and a case control study, by Ji BT et al, 
showed that intake of alcohol was not associated with increased risk of pancreatic 
carcinoma. In our study, only 15 % of patients were alcoholics. 
 
Palpable gallbladder 
 Although all cases had distended gallbladder in USG and in laparotomy. 
Only in 42 % of cases gallbladder was palpable clinically,in our study. According 
to Michael J.Zinner et al, and A cuschieri et al, 25 – 30 % of patients presented 
with palpable gallbladder.  
  So, all distended gall bladder may not be palpable in clinical examination 
and absence of palpable gallbladder in obstructive jaundice does not  rule out the 
periampullary carcinoma. 
 
Hepatomegaly 
 According to Michael U Zinner et al, and A cuschieri et al, 25 -30 % of 
patients present with nonmetastatic hepatomegaly. In our study, it was 26 %. It is 
probably congestive hepatomegaly due to biliary obstruction. 
 
 So presence of hepatomegaly in patients with periampullary carcinoma 
does not denote metastasis.  
 
Extent of disease 
 Liver metastases are present in 50 % of cases (Michael Trede, Dennis A 
casciato et al). In our study, it was 46.15 %. 
 Ascites is present in 25 % of cases (Dennis A. Casciato et.al). In  our study 
it was 26.92 %. 
 
 At the time of presentation it is unusual to have patients with duodenal 
obstruction from the tumor , but 15% to 20% develop it sometime before they die 
(Tada Taka Yamada et al). In our study, it was 31% at the time of presentation. 
 
 Retrospective reviews of surgical series (Sarr MG et al, Singh SM et al, 
Watanapa et al. and prospective randomized trials of endoscopic palliation 
(Bornman PC et al, Dowsett JF et al, Shephard HA et al) have demonstrated that 
in 10% to 20% of patients with irresectable pancreatic carcinoma,will be presented 
with Late onset of gastric outlet obstruction which may require a 
gastrojejunostomy (Tada Taka Yamada et al) 
          
        . Prophylactic gastrojejunostomy is not associated with increased morbidity 
and mortality ( Lillemoe KD, Sauter PK Pitt et al). 
 In our study, out of 11 cases of irresectable carcinoma, 2 cases developed 
gastric outlet obstruction. 6 months after the palliative surgery. 
 So it is necessary to do prophylactic gastrojejunostomy in patients with 
irresectable carcinoma undergoing palliative procedure to avoid the future surgery 
in these patients. 
 
Size of tumor  
 The size of tumor in resectable carcinomas usually ranges from 2-3 cms. 
(Tsuchiya R et al, Trede M et al), In our study, it was 2.5 – 3.5 cm. 
  Tumors smaller than 2cm are infrequent (Hermanek P). In our study, No 
patients with tumor 2 cms were seen. 
 In autopsy series, the average size is 4-6 cm (Kloppel G et al, Morohoshi T 
et al, Cubilla AL et al). In our study average size of the tumor was 5 cms and no 
patients with tumor  size more than 4cm had curative resection. 
 CT Scan Abdomen in evaluation of carcinoma 
 Before introduction of spiral CT, dynamic CT was regarded the best 
technique in staging of carcinoma head of pancreas with an accuracy of 90-100% 
for predicting irresectable tumors. (Reznek, Nghiem HV). 
 Sensitivity and specificity of CT scan for irresectability of carcinoma head 
of Pancreas were 56% and 87% respectively (Warshaw et al). 
 In our study, among the 14 patients who had resectable tumour after CT 
scan evaluation, 6 patients had  non-resectable tumour at laprotomy. 
EUS   and laparascopic contact USG are emerging newer diagnostic modalities 
that are recommended to improve preoperative assessment of resectablity.  
 
 
 
Location of Tumors 
 85% of Periampullary carcinomas arise from head of pancreas, 10% from 
ampulla of Vater and 5% from duodenum and distal CBD (David C. sabiston Jr). 
 In our study, 58% of carcinoma from head of pancreas, 27% from the 
ampulla of Vater, 8% from distal CBD and 8% of duodenum. 
 
Management 
 Surgical resection by pancreatico-duodenectomy provides the only chance 
for cure for patients with periampullary carcinoma. However, 25% - 75% of 
patients who undergo exploratory surgery with intention to perform a pancreatico-
duodenectomy are found to have unresectable disease (Trede M, Singh SM et al, 
Sohn TA et al). Therefore, at the time of surgery, the surgeon must focus on 
appropriate palliation of disease. 
 
 In our study, 42.85% of patients who were posted for curative surgery, had 
unresectable tumor  at laparotomy. In all these patients, there was local infiltration 
superior mesenteric vessels and portal vein, which was not identified 
preoperatively. The rest of 57.14% of patients underwent curative surgery. 
 
 In patients who had curative resection, 62.5% were ampullary tumors and 
25% were carcinoma head of pancreas. 
 The reason for better resectability of carcinoma of ampulla of Vater is early 
diagnosis which is due to early development of jaundice which brings the patients 
in early stage for medical attention and treatment (Helmut Friess et al). 
 In study by Sohn et al, the carcinoma head of pancreas accounted for 94% 
of unresectable tumors, ampulla of Vater 2%, the carcinoma of duodenum 1% and 
carcinoma of distal CBD 3%. 
 In our study, the carcinoma head of pancreas accounted for 86.7% of 
unresectable tumors, ampulla of Vater 28.6 %, the carcinoma of duodenum 50%, 
and distal CBD 100 %. 
 
POST OPERATIVE COMPLICATION 
Curative cases 
During the 1960’s the operative mortality after pancreatico-duodenectomy 
was in the range of 22-40% with postoperative morbidity rates as high as 40% 
(Monge JJ et al, Lansing RN et al, Gilsdorf RB et al) 
During last decade a dramatic decline in operative morbidity and mortality 
after the pancreatic-duodenectomy has been reported with operative mortality 
ranging from 2-3%(Grace PA et al, Braasch, Trede M, Cameron JL) 
 
 In our study there was operative mortality is 25%.The high operative 
mortality (25%) of our study may be attributable to various negatively or 
adversely influencing factors like lack of established medical / radiation oncology 
departments, low volume of cases done, the ‘early learning curve’ effect, and may 
be the still poorly understood phenomenon of ‘Biological behavior’. 
 
 The study by Lieberman et al, showed that volume of cases done had the 
major impact on survival. 
 
 With better intensive care facilities and well equipped medical /radiation 
oncology departments, an established hepatobiliary unit, and hence a higher 
volume of cases, the mortality rates may decline, only to merit the higher process 
of surgical technique. 
 Complication rates following pancreaticoduodenectomy remain high, 
however usually in excess of 25-35%. Pancreatic fistula remains the most common 
serious complication with its incidence ranging from 5-20% (Michael J Zinnner et 
al). In our study it was 37.5%. 
 
Palliative cases:  
The operative mortality (within 30 days mortality) following palliative 
bypass was 12% in Watanapa P et al study and 0% in our study. 
 In a study by Lilleomoe et al , the wound infection ( 10% ) was the 
commonest complication of  Bypass surgery, followed by delayed gastric 
emptying (8%.) In our study, the wound infection was 27.3% and delayed gastric 
emptying was 9.1 % 
CONCLUSION 
1. The incidence of periampullary carcinoma in our region was 1.15% of all 
carcinomas and carcinoma head of pancreas accounted for the majority. 
2. There was slight male preponderance (Male to Female ratio 1.8:1) 
3. Most of the Carcinomas occurred in the age group of 40-69. 
4. Jaundice and abdominal pain were the most common presenting symptoms. 
5. Recent onset of diabetes mellitus was present in 15.38% of the cases. 
6. 54% of the patients were smokers for > 15yrs of duration. 
7. Most of the patients who presented with weight loss and abdominal pain 
had unresectable tumor. 
8. CT Scan abdomen was the modality of investigation to know the 
resectability. 
9. Most of the patients were presented with irresectable carcinoma at 
presentation (Tumor resectability rate: 30.76%) 
10. Size of tumor in patients who underwent curative surgery, was 2.5-3.5 cms. 
No patients with size of the tumor above 4 cm had resectable carcinoma. 
11. The mortality rate of periampullary carcinoma in this study: 25% and  
      anestamotic leak rate :37%. 
12. Median survival of our patients who underwent  curative  resection for   
      non - pancreatic periampullary lesion  are 12 to 18 months  and for          
       pancreatic  periampullary carcinoma  are 9 to 12 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epidemiology and Risk Factors in Pancreatic Cancer 
 
 
Factors Increased Risk Possible Risk Unproven Risk Decreased Risk
Demogra
phic 
Advancing age  
Black race 
Male gender 
Jewish ethnicity 
Geography Socioeconomic status  
Host HNPCC 
Familial breast 
cancer 
Peutz-Jeghers 
Ataxia-
telangiectasia 
FAMMM 
Hereditary 
pancreatitis 
Diabetes 
Chronic pancreatitis
Endocrine tumors 
Cystic fibrosis 
Sex hormones 
Pernicious anaemia 
Peptic ulcer surgery 
Cholecystevtomy 
Tonsillectomy  
Allergic 
disorders 
 
Environm
ental  
Tobacco Diet  
Occupation 
Alcohol 
Coffee 
Radiation  
 
 
 
 
 
 
 
 
 
 
  
Algorithm for the staging of pancreatic tumors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complications of Pancreaticoduodenectomy 
History Clinical Examination 
Sonography
Double-Spiral CT or MRI 
ERCP
Endosonography
Angiography 
Operable 
Laparoscopy 
Inoperable 
Needle
Expl.Laparotomy 
Resection Palliative Bypass 
Common Uncommon 
Delayed gastric emptying Fistula 
Pancreatic fistula  Biliary 
Intra-abdominal abscess Duodenal 
Hemorrhage Gastric 
Wound infection Organ failure 
Metabolic 
           Diabetes  
           Pancreatic 
exocrine insufficiency  
Cardiac 
Hepatic  
Pulmonary 
Renal 
Pancreatitis 
Marginal ulceration 
 
Complications of surgical palliation cases 
Wound infection 
Cholangitis 
Delayed gastric emptying 
Biliary anastomotic leak 
CVS/RS/GUS complications 
 
 
 
 
 
Algorithm for Palliation of obstructive jaundice 
  
 
 
 
 
 
 
 
Algorithm for Management of Gastric outlet obstruction 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Patients with Locally advanced or 
Metastatic Unresectable Pancreatic 
Cancer 
Symptomatic Obstructive 
Jaundice 
LAPAROTOMY  - STAGED  LAPAROSCOPY - STAGED   
SURGICAL   ENDOSCOPIC RADIOLOGIC   
Cholecystojejunostomy   
Choledochojejunostomy   
Hepaticojejunostomy   
Standard Stent 
Expandable Wall Stent 
PTH Internal -external Stent 
PTH Internal -only Stent   
PTH Expandable Wall Stent 
PTH Trans -wall Stent   
PTH “Stent Tumorectomy” 
 
Recurrent Biliary  
Obstruction   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
Pancreatic Cancer Patient 
Double Spiral CT Scan 
Without Demonstrated Gastric Outlet Obstruction 
CT Scan Staged Unresectable Disease 
Histology Proven Pancreatic Cancer 
CT Scan Assessed Equivocal or 
Potentially Resectable 
Pancreatic Cancer 
Non-Operative Treatment Staging Laparoscopy Prior to 
Proceeding with Laparotomy 
Laparotomy for Staging  
and Potential resection 
Resectable Pancreaticoduodenectomy Resectable
Locally – advanced  or 
Metastatic Unresectable 
Disease 
No Gastric Outlet 
Obstruction Until 
Death
No Prophylactic Bypass Prophylactic Bypass 
No Gastric 
Outlet 
Obstruction 
Until Death 
Gastric Outlet 
Obstruction 
Gastrojejunotomy 
Endoscopic Duodenal Stent 
Endoscopic Gastrotomy Tube 
Radiologic Duodenal Stent 
 
 
 
 
 
Algorithm for management of pain 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
FINDING AT EXPLORATION 
 
 
Findings contraindicating resection 
 
 
Findings not contraindicating 
resection 
 
Liver metastasis (any size) 
Celiac lymph node involvement 
Peritoneal implants 
Invasion at duodenum or distal stomach 
Involved peripancreatic lymph nodes 
Involved lymph nodes along the porta 
hepatis that can be swept down with the 
  
  
  
  
  
           Fail 
  
  
  
  
  
  
  
  
  
  
           Fail            Fail   
  
Conventional Narcotic Anaelgesics  
- Oral   
- Transdermal  
- Intravenous  
  
- Oral   
PERCUTANEOUS  LAPAROTOMY   VATS     
    
      
- Nerve transaction   
  
Separate procedure   
Requires hospitalization   
Long - term analgesia   
  
-Ethanol 
-Phenol 
 
Outpatient procedure 
Short-tarn analgesia 
May be repeated 
 
-Ethanol 
 At staging laparotomy or 
during palliative procedure   
 Requires hospitalization 
Short-term analgesia   
Dual-phase helical CT
Absence of 
pancreatic mass 
ERCP ± EUS 
Pancreatic mass suspicious Alternative diagnosis
Invasion of transverse mesocolon 
Hepatic hilar lymph node involvement 
 
specimen. 
 
 
 
 
STAGE GROUPING 
 
 
Stage Grouping Description 
Ia T1 No Mo Tumor confined to pancreas 
Ib T2 No Mo Tumor invades duodenum and / or bile duct outside 
pancreas no lymph node involvement 
II T3 No Mo Tumor has not spread beyond duodenum or bile duct, 
but includes regional lymph nodes 
III Any T, N1 Mo Locally advanced tumor growing into blood vessels, 
stomach, spleen, and colon, with or without lymph 
node involvement 
IV Any T, Any N, M1 Distant metastases (liver, lungs) present 
 
 
 
 
 
Pre operative staging  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
History, physical examination, initial laboratory studies = suspicion of pancreas CA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INCIDENCE OF PERI AMPULLARY CARCINOMA 
 
Periampullary Carcinoma 26 1.15 % 
Other 2234 98.84 % 
Total Cancers 2260 100 % 
 
 
SITE OF CANCERS 
 
Site Of Cancers No. of Cases Percentage 
Carcinoma Head of Pancreas 15 57.69 % 
Carcinoma of Ampulla of Vater 7 26.92 % 
Carcinoma of Distal CBD  2 7.69 % 
Duodenal Carcinoma 2 7.69 % 
Total  26 100 % 
 
AGE INCIDENCE  
 
Age Group No.of Cases Percentage
<30 - 0 
30-39 2 7.69 
40-49 7 26.92 
50-59 10 38.46 
60-69 5 19.23 
Above 70 2 7.69 
Total  26 100 
 
SEX INCIDENCE 
 
 
Male Female Age Group 
No.of Cases Percentage No.of Cases Percentage
<30 - -  - 
30-39 1 5.88 1 11.11 
40-49 5 29.41 2 22.22 
50-59 6 35.29 4 44.44 
60-69 3 17.64 2 22.22 
Above 70 2 11.76 - - 
Total  17 100 9 100 
 
 
 
SYMPTOMATOLOGY 
 
 
Symptoms No. of Patients Percentage 
Pain 19 73.07 
Jaundice 22 84.61 
Weight Loss 14 53.84 
Vomiting 12 46.15 
Upper GI Bleed 11 42.30 
 
 
 
 
 
 
 
 
 
 
 
 
EXTENT OF DISEASE 
 
 
 
Extent Of Disease No. of Cases Percentage
Liver Secondaries 12 46.15 
Ascites 7 26.92 
Pleural Effusion  2 7.69 
Enlargement of left Supraclavicular Node 2 7.69 
Duodenal Obstruction 8 30.76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT OF CARCINOMA HEAD OF PANCREAS 
 
 
Management No. of Patients Percentage 
Curative surgery 2 13.33 % 
Palliative Biliary 
Bypass 
3 20 % 
Palliative Biliary and 
Gastroenteric Bypass  
4 26.66 % 
Conservative  4 26.66 % 
Referred for stenting 2 13.33 % 
Total 15  
 
 
 
 
 
TREATMENT OF CARCINOMA AMPULLA OF VATER 
 
 
Management No. of Patients Percentage 
Curative resection 5 71.42 
Palliative Biliary 
Bypass 
2 28.57 
 
 
 
 
 
 
 
 
 
 
 
 
 
MANAGEMENT OF PERIAMPULLARY CARCINOMA 
 
 
Management No. of Patients Percentage 
Curative Surgery 8 30.76 
Palliative Biliary 
Bypass 
5 19.23 
Palliative Biliary and 
Gastroenteric Bypass 
6 23.07 
Referred for stenting 2 7.69 
Conservative  5 19.23 
Total  26 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARITIVE ANALYSIS OF AGE GROUP 
 
 
Age group Shantha V et al79 Our Study 
<30 2.63 0 % 
30-49 2.63 7.69 % 
40-49 26.31 26.92 % 
50-59 18.42 38.46 % 
60-69 34.22 19.23 % 
>70 15.49 7.69 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARATIVE ANALYSIS OF SYMPTOMATOLOGY IN 
UNIVERSITY OF MANNHEIM STUDY  WITH OUR STUDY 
 
 
 
University of Mannheim  
Study 
Our study Symptoms   
No.of Patients Percentage No.of Patients Percentage
Jaundice 332 82 22 84.61 
Pain 301 75 19 73.07 
Vomiting 77 29 12 46.15 
Weight loss 346 85 14 53.84 
Diabetes 9 2.2 4 15.38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARATIVE ANALYSIS OF LOCATION OF TUMOURS 
 
 
Location Sohn et al Our study 
Head 70.22 % 57.69 % 
Ampulla 10.78 % 26.92 % 
Distal CBD 10.00 % 7.69 % 
Duodenum 9.00 % 7.69 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARATIVE ANALYSIS OF UNRESECTABLE TUMOURS 
 
 
Location Sohn et al Our study 
Head of Pancreas 94 % 86.66 % (13/15) 
Ampulla of Vater 2 % 28.57 % (2/7) 
Duodenum 1 % 50 % (1/2) 
Distal CBD 3 % 100 % (2/2) 
 
 
COMPARATIVE ANALYSIS OF OPERATIVE MORTALITY 
 
 
Author Year No.of Patients Operative 
Mortality % 
Grace 1986 45 2.2 
Braach 1986 87 2.2 
Trede 1990 118 0 
Cameron 1991 80 1.3 
Cameron 1993 145 0 
Our Study 
(Different 
Surgeons) 
2004 - 2006 8 25 % 
 
 
 
 
 
 
 
THE TREATMENT OPTIONS FOR 
PERIAMPULLARY CARCINOMA 
 
Curative resection 
                 Whipple’s pancreatico duodenectomy 
                 Sphincter preserving pancreatico-duodenectomy 
Palliative treatment 
Relief of Jaundice 
- Biliary enteric anastomosis 
- Cholecystojejunostomy 
- Choledochojejunostomy 
- Hepaticojejunostomy 
- Endoscopic Transhepatic stenting 
Relief of duodenal obstruction 
- Gastrojejunostomy 
Relief of pain 
- Analgesics, opiods 
- Coeliac plexus block 
- Cordotomy 
- Extensive Sympathectomy 
- Sterotactic thalamotomy 
- Pancreatico gastrostomy over a T tube. 
- Transthoracic splanchniectomy 
 
 
 
 
 
 
 
DIAGNOSIS AND STAGING 
 Invasive 
Sonography 
Laparoscopic 
Endoscopic 
Intraportal 
 
Angiography 
ERCP 
Laparoscopy, including peritoneal cytology 
Fine-needle cytology 
Immunocytochemical examination of blood and bone marrow  
Noninvasive 
Transabdominal sonography 
CT scanning (contrast enhanced, helical) 
Ultra fast MR imaging, including 
MR cholangiopancreatography 
MR angiography 
MR with Echoplanar Imaging (EPI-MR) 
Positron-emission tomography 
Tumor marker: CA 19-9 
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PERIAMPULLARY CARCINOMA – PROFORMA 
 
Name      Ward / Unit 
Age/Sex     D.O.A 
Occupation     D.O.D 
I.P.No.     D.O.S 
 
DIAGNOSIS  
 
Complaints   Yes/No     Duration   Complaints           Yes/ No     Duration 
        
Jaundice       Haemetemesis 
        Melena 
Pain        Clay coloured 
         Stools 
Loss of        Fever 
Weight 
Vomiting      Anorexia 
Past History HT       TB 
  DM     Previous Surgery 
Personal History 
Diet   Smoking   Alcohol 
Family History    Socioeconomic status 
General Examination 
Built 
Nourishment     Pedal edema 
Jaundice     Lymphadenopathy 
Hydration     Anaemia 
 
Vital Signs 
Pulse:   B.P:  Temp:  R.R: 
Other Systems 
Per-Abdomen 
Gallbladder   Liver    Ascitis 
PR: Rectal Deposit 
Investigations 
Urine-Alb  Sr.Na+ mEq/L 
Sugar  Sr.K+ mEq/L 
Urobilinogen  Sr.Protein(T) g % 
Bile Salts  A/G Ratio  
Bile Pigments  Sr.SGOT U/L 
Hb g % Sr.SGPT U/L 
Blood sugar mg % Sr.ALP U/L 
Blood Urea mg % CT  
Sr.Creatinine mg % BT  
Sr.Bilirubin mg % PT Secs  
X-ray Chest 
Barium Meal Series 
OGD-Scopy 
USG-Abdomen 
CT-Scan: Abdomen 
Biopsy 
Treatment:  Conservative/Surgery 
Surgery: Anaesthesia   Incision 
  Findings                       Procedure 
 
Complications 
Follow-up 
 
 
 
 
 
 
 
 
                                                                MASTER CHART 
 
Symptoms  Clinical  
Examinations  
Lab
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1 Narayanan 59 M 862415 + - - - - - - - + + - - 10
2 Adaikappan 54 M 836558 + - - - - - + + + + - - 9.6
3 Jeyaraman 53 M 913381 + - - - - + - - - - - - 9.8
4 Marimuthu 47 M 907376 + + + + - - + - + + - - 8.6
5 Saroja 45 F 901067 + - - - - - - - - - - - 9.2
6 Samsulsudha 54 F 903906 + - - - - - - - - - - - 10
7 Ammani 65 F 998063 + - - - - - - - + + - - 8.8
8 Balamani 48 F 808810 - + + + + - - - - - - - 9.4
9 Ramaiyan 48 M 888722 + + + + - - + - + + - - 9.2
(Contd.)            
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C.A.V 
3 - - - W.P.D Wound 
infection 
18 month 1 
C.A.V 
 
2.5 - - - W.P.D Panc. leak 12 month 2 
 
C.A.V 
3.5 - - - W.P.D Death - 3 
C.H.P 
with D.O 
 
3.5 - - - W.P.D Panc. leak 9month 4 
 
Duodenal 
Carcinoma 
3.5 - - - W.P.D No 
complication 
16month 5 
C.A.V 
 
3 - - - W.P.D Wound 
infection 
Last 
follow up 
6 
C.A.V 
 
3 - - - W.P.D Leak Last 
follow up 
7 
C.A.H 
 
4 - - - W.P.D Death - 8 
 
C.A.H 
with D.O 
6.5 - - - C.J 
&G.J 
-  9 month 
Symptom 
free 
9 
  
 
 
 
Symptoms  Clinical  
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10 Kaliaperumal 55 M 799161 + + + + + - + - - + - - 7.8
11 Mani 49 M 840538 + + + + + + + - - - - -   9.8
12 Ponnaiyan 58 M 804662 + + - + - - - - + - + - 8.6
13 Babujohn 39 M 836146 + + + + + + + + - - + - 8.2 
14 Murugaiyan 45 M 838599 + + - - + - + - - - + - 8.4
15 Kasinathan 40 M 762954 + + - - + - - - - - + - 9.8
16 Lakshmi 65 F 835143 + + + - - - - - - + - - 10.4
17 Vasantha 50 F 889385 + + + - + - - - + - - - 9.6
18 Rukmani 54 F 816875 + - - + + - - - - - + - 10.6
 
 
(Contd.) 
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Preoperative Findings  
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C.A.H with 
D.O 
7 - - + C.J & G.J Wound unfection 9 month symptom free 10 
C.A.H with 
D.O & D.M 
 
8 - - + C.J & G.J Nil Last follow up 11 
C.A.H with HS 
 
6.5 + - + C.J & J.J Nil GOO After 6 Months 12 
C.A.H with HS 
 
8 + - + C.J & J.J Delayed Gastric 
empty 
 - 13 
C.A.V with HS 
 
6.5 + - + C.J & J.J Wound infection Last follow up 14 
C.B.D with HS 
 
7.5 + - + C.J &J.J Nil Last follow up 15 
C.A.H with 
D.O 
 
7 - - + C.J & G.J  Wound infection  Last follow up 16 
C.A.V with 
D.O 
 
6 - - + C.J & G.J Nil Last follow up 17 
C.A.H with HS 
 
6 + - + C.J & J.J Nil Last follow up 18 
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19 Aleemabeevi 56 F 878475 + + - + - - - - + - + - 8.2 102
20 Gabriel 65 M 758436 + + + + + - + + - - + - 9 78
21 Somasundharam 70 M 834897 + +     
- 
+ - - + + - - + - 9.8 120
22 Sivaraman 67 M 894564 - + + - + - + - + - - +   
23 Natrajan 65 M 909865 - + - + - + + - + - - - 10 150
24 Ramu 59 M 889822 + + - + - - - - - - - - 10.4 64
25 Appakannu 76 M 910360 + + + + + - + - - - - - 8.6 96
26 Murugamani 39 F 746597 - + + + - - - - + - - + 6.4 78
 
DM :  Diabetes Mellitus   HS : Hepatic Secondaries 
   USG :  Ultrasonogram 
SCN :  Supra Clavicular Node  PE : Pleural Effusion 
   DO :  Duodenal Obstruction   
ALP :  Alkalaine Phosphatase  CAV : Carcinoma Ampulla 
of Vater    WPD : Wipple’s Pncreaticoduodenectomy 
CXR :  Chest Xray    CAH : Carcinoma Head of 
Pancreas     A : Ascites. 
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C.B.D 
with HS 
7 + - + C.J &J.J  GOO 
After 6 
Months 
19 
DC 
with  
DO & 
HS & A  
 
- - - - Conservative  Referred 
for 
stenting 
 20 
C.A.H 
with HS 
& A 
 
- - - - Conservative Referred 
for 
stenting 
 21 
C.A.H 
with HS 
& A 
- - - - 
 
Conservative   22 
C.A.H 
with HS 
& A 
- - - - 
 
Conservative   23 
C.A.H 
with HS 
& A 
- - - - 
 
Conservative   24 
C.A.H 
with HS 
& A & 
PE 
- - - - 
 
Conservative   25 
C.A.H 
with HS 
& A & 
PE 
- - - - 
 
Conservative   26 
 
   CJ : Cholecysto Jejunostomy  GOO : 
 Gastric Outlet Obstruction 
(Contd.) 
   JJ : Jejuno Jejunostomy   CBD :
 Common Bile Duct 
   GJ : Gastro Jejunostomy 
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